Chase Knickerbocker

David Amsellem

Christian Glennie

Paul Cuddon

Thibault Boutherin

Brandon Folkes

Brian Balchin

Carl Byrnes

Dennis Ding

- Indivior plc reported **Q3 2025 total net revenue of $314 million**, a **2%** increase year-over-year, with **SUBLOCADE net revenue growing 15% to $219 million** and adjusted EBITDA increasing **14% to $120 million**.  **[0001625297_2215701_4]** 
- The company raised its **full-year 2025 financial guidance**, now expecting total net revenue between **$1.18 billion and $1.22 billion** and adjusted EBITDA between **$400 million and $420 million**, reflecting a **15%** increase versus 2024 at the midpoint.  **[0001625297_2215701_4]** **[0001625297_2215701_5]** 
- Strategic actions under the "Indivior Action Agenda" are expected to result in an annual reduction of operating expenses of at least **$150 million** compared to 2025, with the **2026 operating budget not exceeding $450 million**.  **[0001625297_2215701_1]** **[0001625297_2215701_5]** **[0001625297_2215701_9]** 
- These actions include consolidating operating footprint, restructuring R&D and medical affairs, discontinuing OPVEE sales and marketing, and optimizing the rest of world business.  **[0001625297_2215701_1]** **[0001625297_2215701_2]**

Indivior plc Reports Strong Q3 2025 Results and Raises Full-Year Guidance

- Indivior reported **Q3 2025 Total Net Revenue of $314 million**, a **2% increase** year-over-year, driven by **SUBLOCADE Net Revenue of $219 million**, which grew **15%** year-over-year.  **[0001625297_2215078:3]** **[0001625297_2215078:5]** 
- The company's **Adjusted EBITDA for Q3 2025 was $120 million**, marking a **14% increase** from Q3 2024, and **Non-GAAP Net Income grew 42% to $93 million**.  **[0001625297_2215078:3]** **[0001625297_2215078:5]** 
- Indivior has **raised its Full-Year 2025 financial guidance**, with Total Net Revenue now projected between **$1,180 million and $1,220 million** and Adjusted EBITDA between **$400 million and $420 million**.  **[0001625297_2215078:6]** 
- The company is making progress on its "Indivior Action Agenda," including organizational simplification efforts that are expected to generate **at least $150 million in annual expense savings in 2026**.  **[0001625297_2215078:4]** **[0001625297_2215078:6]**

Indivior Reports Strong Q3 2025 Results and Raises Full-Year Guidance

- Indivior reported **Q3 2025 total net revenue of $314 million**, up **2% year-over-year**, with **SUBLOCADE® net revenue growing 15% year-over-year to $219 million**.  **[1625297_20251030PH10766:0]** **[1625297_20251030PH10766:1]** 
- The company **raised its full-year 2025 financial guidance**, now expecting total net revenue between **$1,180 million and $1,220 million** and adjusted EBITDA between **$400 million and $420 million**.  **[1625297_20251030PH10766:1]** 
- Strategic actions, including optimizing the Rest of World (ROW) business and discontinuing sales and marketing support for OPVEE®, are expected to generate **at least $150 million in annual operating expense savings beginning in 2026**.  **[1625297_20251030PH10766:0]** 
- For Q3 2025, GAAP net income was **$42 million** with diluted EPS of **$0.33**, and adjusted EBITDA increased **14% to $120 million**.  **[1625297_20251030PH10766:1]** **[1625297_20251030PH10766:5]** **[1625297_20251030PH10766:10]**

Indivior Reports Q3 2025 Results and Raises Full-Year Guidance

- Indivior reported **Q3 2025 Total Net Revenue of $314 million**, an increase of **2%** year-over-year, driven by **SUBLOCADE Net Revenue of $219 million**, up **15%** year-over-year.  **[1625297_0001193125-25-257381_d58033dex991.htm:0]** **[1625297_0001193125-25-257381_d58033dex992.htm:1]** 
- The company **raised its Full-Year 2025 financial guidance**, now expecting **Total Net Revenue between $1,180 million and $1,220 million** and **Adjusted EBITDA between $400 million and $420 million**.  **[1625297_0001193125-25-257381_d58033dex991.htm:1]** **[1625297_0001193125-25-257381_d58033dex992.htm:2]** 
- Strategic actions, including the optimization of the Rest of World business and discontinuing sales and marketing support for OPVEE, are projected to generate at least **$150 million in annual operating expense savings beginning in 2026**.  **[1625297_0001193125-25-257381_d58033dex991.htm:0]** **[1625297_0001193125-25-257381_d58033dex993.htm:1]**

- Indivior PLC announced the publication of clinical trial results in *JAMA Network Open* demonstrating that **rapid induction** with SUBLOCADE® led to **higher treatment retention rates** for individuals with moderate-to-severe opioid use disorder (OUD) compared to standard induction.  **[1625297_20251015PH97591:0]** 
- The study found that rapid induction, involving a single 4-mg oral buprenorphine dose followed by a same-day SUBLOCADE injection, was well tolerated and particularly effective among **fentanyl-positive participants**.  **[1625297_20251015PH97591:0]** 
- The trial also showed that administering the second SUBLOCADE injection one week after the first was well tolerated, reinforcing the potential for an agile and patient-centered treatment model.  **[1625297_20251015PH97591:0]**

Indivior Publishes Positive Clinical Trial Results for SUBLOCADE® Rapid Induction

- Indivior PLC intends to **redomicile from the U.K. to the U.S.**, establishing a new U.S. parent company, Indivior Pharmaceuticals, Inc. (IPI), above its existing U.K. parent company.  **[1625297_20251001PH87422:0]** 
- The proposed change aims to **maximize the benefits of its U.S. Nasdaq listing**, including expanding U.S. capital markets presence, increasing potential U.S. equity indexation, and simplifying corporate governance.  **[1625297_20251001PH87422:0]** 
- Shareholders of Indivior PLC will receive **one new IPI share for each Indivior PLC share held**, with IPI's common stock continuing to trade on Nasdaq under the symbol INDV.  **[1625297_20251001PH87422:0]** 
- The transaction is expected to become effective in **late January 2026**, following a shareholder vote at an Extraordinary General Meeting (EGM) in early December 2025.  **[1625297_20251001PH87422:0]**

Indivior Proposes U.S. Domiciliation

- Indivior PLC initiated the "Indivior Action Agenda" in **Q2 2025**, a **three-phased, multi-year operational roadmap** designed to maximize business potential and create shareholder value.  **[1625297_0001625297-25-000059_indv-20250826.htm:1]** 
- On **August 26, 2025**, the company began implementing Phase 1 initiatives, which include **headcount reductions** and **real estate consolidations**, aimed at simplifying the organization and eliminating non-essential activities.  **[1625297_0001625297-25-000059_indv-20250826.htm:1]** 
- These actions are expected to result in pre-tax restructuring charges of approximately **$39 to $50 million**, with **$27-$35 million** being cash, primarily recognized in **Q3 and Q4 2025**.  **[1625297_0001625297-25-000059_indv-20250826.htm:1]**  These charges consist of **$16-$19 million** for employee severance, **$15-$22 million** for real estate consolidation, and **$8-$9 million** for consulting, legal, and tax planning.  **[1625297_0001625297-25-000059_indv-20250826.htm:1]** 
- Indivior is also exploring strategic alternatives for its OPVEE® product and non-U.S. business.  **[1625297_0001625297-25-000059_indv-20250826.htm:1]**

INDIVIOR (INDV)